<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-542" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>New Onset Diabetes After Transplant</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Solhjoo</surname>
            <given-names>Mahdis</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Salini C.</given-names>
          </name>
          <aff>SUNY, Stony Brook</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mahdis Solhjoo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Salini Kumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-542.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>New-onset diabetes mellitus after transplantation (NODAT) is the development of diabetes mellitus after solid organ transplantation. NODAT frequently occurs, increasing the risk of infection as well as mortality rates. The appropriate evaluation and management of NODAT by the health care providers result in prompt diagnosis with a subsequent decrease in morbidity and mortality associated with this condition and increases the organ survival after a transplant. This activity describes the pathophysiology, evaluation, and management of NODAT and highlights the role of the interprofessional team in caring for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of new-onset diabetes mellitus after organ transplantation.</p></list-item><list-item><p>Outline typical laboratory findings for a patient with new-onset diabetes mellitus after organ transplantation.</p></list-item><list-item><p>Explain the treatment considerations for patients with new-onset diabetes mellitus after organ transplantation.</p></list-item><list-item><p>Review the importance of collaboration and coordination among the interprofessional team to enhance patient care, facilitate treatment planning, and increase patient survival following organ transplantation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=542&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=542">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-542.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>New-onset diabetes mellitus after transplantation (NODAT)&#x000a0;is&#x000a0;the occurrence of diabetes mellitus (DM) in a previously non-diabetic person after solid organ transplantation.&#x000a0;NODAT&#x000a0;frequently occurs after organ transplantation and increases the risk of infection&#x000a0;and mortality rates.<xref ref-type="bibr" rid="article-542.r1">[1]</xref><xref ref-type="bibr" rid="article-542.r2">[2]</xref></p>
        <p>&#x000a0;International Consensus Guidelines on NODAT were published in 2003. They recommended that the diagnosis of NODAT should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes. It is&#x000a0;suggested to the use of modified ADA 2003 criteria to define NODAT and impaired fasting glucose in kidney transplant recipients.</p>
      </sec>
      <sec id="article-542.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Patients&#x000a0;who have&#x000a0;preexisting risk factors for type 2 DM are more prone to develop NODAT. NODAT risk factors subclassify into two groups of nonmodifiable and&#x000a0;modifiable risk factors.</p>
        <p>
<bold>Nonmodifiable Risk Factors</bold>
</p>
        <p>
<bold>Age</bold>
</p>
        <p>Age&#x000a0;is among the greatest risk factors in the development of&#x000a0;NODAT. Studies demonstrated that&#x000a0;the incidence of NODAT is 2.2 times higher in transplant recipients who are more than 45 years of&#x000a0;age&#x000a0;compared to younger adults.</p>
        <p>
<bold>Ethnicity</bold>
</p>
        <p>NODAT is more common in the Black and Hispanic population compared to the White population. This difference in the incidence of NODAT can be due to the genetic diversity&#x000a0;and&#x000a0;variable effects of immunosuppressive agents on various ethnicities. As an example, tacrolimus has been reported to be a more potent&#x000a0;cause of&#x000a0;NODAT in the Black population.&#x000a0;</p>
        <p>
<bold>Family History of Diabetes Mellitus and Genetic</bold>
</p>
        <p>Genetic factors&#x000a0;are known to be important in NODAT. Based on the evidence, NODAT is more common in people with a history of diabetes in their first-degree relatives. The development of NODAT has genetic links to the alleles of human leukocyte antigen (HLA) A28, A30, B27, and Bw42. The association between single nucleotide polymorphisms (SNPs) and risk for NODAT has been documented in multiple studies. Also, studies show that the association of the R325W polymorphism in the SLC30A8 zinc transporter gene with the R/r inheritance relates to a higher risk of NODAT.&#x000a0;Other specific gene variants which are associated with NODAT are KCNQ1,&#x000a0;TCF7L2,&#x000a0;KCNJ11-Kir6.2, and NFATc4.&#x000a0;TCF7L2. These variants relate to impaired&#x000a0;insulin secretion and an&#x000a0;accelerated rate of gluconeogenesis. Pathogenesis of NODAT in kidney transplant recipients demonstrates a relationship to significant variations of IL-7R, IL-17E, IL-17R, and IL-17RB.</p>
        <p>
<bold>Pre-diabetes Status</bold>
</p>
        <p>Abnormal glucose tolerance is another risk factor for NODAT. Patients with pre-diabetic conditions such as fasting blood sugar&#x000a0;levels between 90 and 100&#x000a0;mg/dL need to be monitored closely post-transplant and advised on lifestyle modifications to&#x000a0;avoid weight gain, which on its own can tip the patient&#x000a0;to develop diabetes mellitus.&#x000a0;</p>
        <p>
<bold>Modifiable Risk Factors</bold>
</p>
        <p>
<bold>Obesity</bold>
</p>
        <p>Obesity confers a significant modifiable risk factor&#x000a0;for the development of&#x000a0;NODAT. It&#x000a0;acts by upregulating of&#x000a0;inflammatory markers and C-reactive protein levels. Adipose tissue increases the production of&#x000a0;tumor necrosis factor-alpha (TNF-alpha), which causes defects in the phosphorylation of the glucose receptor and decreases the expression of insulin-sensitive glucose transporters. This mechanism&#x000a0;leads to insulin resistance and DM. Furthermore, adipose tissue induces&#x000a0;IL-6 synthesis, which is associated with glucose intolerance. Increasing&#x000a0;in adipose tissue results in the reduction of adiponectin, a hormone that reduces&#x000a0;the risk of DM. In&#x000a0;transplant recipients, the level of&#x000a0;adiponectin is low before transplant, which in turn is a risk factor to develop NODAT.&#x000a0;</p>
        <p>
<bold>Post-transplant Medications</bold>
</p>
        <p>Corticosteroids&#x000a0;are&#x000a0;traditionally associated with hyperglycemia and DM by decreasing peripheral insulin sensitivity, inhibiting pancreatic insulin production and secretion, increasing hepatic gluconeogenesis, and promoting&#x000a0;protein degradation to free amino acids in muscles. The diabetogenic effect of corticosteroids in developing NODAT has been suggested to be related to both the dosage and the duration of therapy. In general, post-transplant steroid therapy increases the risk of NODAT by 42%. While a steroid-free regimen reduces&#x000a0;the&#x000a0;NODAT risk, glucose tolerance can significantly improve by reducing the&#x000a0;daily dose of prednisone to 5 mg or lower&#x000a0;post-transplantation. Using a higher dosage of&#x000a0;prednisolone, such as 0.01 mg/kg/day, will increase the risk of NODAT by 5%.&#x000a0;Calcineurin inhibitors (CNI)&#x000a0;are given to most transplant recipients and&#x000a0;are associated with hyperglycemia. CNI reduces the number of&#x000a0;glucose transporter type 4 (GLUT-4) receptor molecules&#x000a0;on the adipocytes. GLUT-4&#x000a0;is an insulin-regulated protein, and its task is to&#x000a0;transport the glucose into adipocytes and&#x000a0;striated muscle cells. A decrease&#x000a0;in the number of GLUT-4 receptors leads to a reduction of&#x000a0;glucose uptake by these cells, which resultant hyperglycemia. Also, CNIs decrease the pancreatic beta-cell density&#x000a0;by interfering with the activated T-cell signaling in pancreatic beta-cells. As a result, this pathway&#x000a0;activates the mutated genes responsible for DM and leads to&#x000a0;reduced insulin synthesis.&#x000a0;Studies report that the incidence of NODAT is significantly higher in&#x000a0;patients&#x000a0;who got treatment with tacrolimus compared to those who&#x000a0;have had therapy with cyclosporine. Tacrolimus&#x000a0;acts by inhibiting T-cell activity, which results in inhibition of&#x000a0;interleukin-2 synthesis, and leads to a failure of T-cell production. Beyond the mechanism mentioned above, tacrolimus also causes hyperglycemia by reducing&#x000a0;glucokinase activity in pancreatic islets leading to suppression of&#x000a0;glucose-induced insulin release. The effect of tacrolimus in the development of&#x000a0;glucose intolerance is reversible&#x000a0;with drug discontinuation. Sirolimus is another immunosuppressant that has been associated with NODAT, especially when used in combination with CNI. There is no known recognized association between mycophenolate mofetil and azathioprine use and the development of NODAT.</p>
        <p>
<bold>Hypomagnesemia</bold>
</p>
        <p>Hypomagnesemia after transplant is another risk factor for NODAT. CNIs can induce hypomagnesemia by inhibition of the renal magnesium transporter, resulting in&#x000a0;renal magnesium wasting.</p>
        <p>
<bold>Viral Infections</bold>
</p>
        <p>Infection and inflammation are two other factors that contribute to glucose intolerance and the development of DM.&#x000a0;HCV infection has a diabetogenic effect&#x000a0;by causing insulin resistance and decreasing hepatic glucose uptake and glycogenesis. Also, HCV has a cytopathic effect on pancreatic beta cells. Studies show that the incidence of NODAT&#x000a0;is 25.6% in those who are HCV-positive, while it is 14.4% in those with no HCV infection.<xref ref-type="bibr" rid="article-542.r3">[3]</xref><xref ref-type="bibr" rid="article-542.r4">[4]</xref><xref ref-type="bibr" rid="article-542.r5">[5]</xref><xref ref-type="bibr" rid="article-542.r6">[6]</xref><xref ref-type="bibr" rid="article-542.r7">[7]</xref><xref ref-type="bibr" rid="article-542.r8">[8]</xref> Antiviral therapy has been a recommended approach before transplant, but it is still unclear&#x000a0;whether the response to therapy&#x000a0;can&#x000a0;improve glycemic control. Using tacrolimus in patients with HCV&#x000a0;aggravates the risk of&#x000a0;NODAT. Active cytomegalovirus (CMV) infection decreases insulin&#x000a0;secretion by&#x000a0;impairing the pancreatic beta cells. CMV can induce the release of cytokines, which leads to apoptosis and mal-functioning of pancreatic beta-cells. As a result, CMV can predispose the patients to NODAT.<xref ref-type="bibr" rid="article-542.r9">[9]</xref><xref ref-type="bibr" rid="article-542.r10">[10]</xref><xref ref-type="bibr" rid="article-542.r11">[11]</xref><xref ref-type="bibr" rid="article-542.r12">[12]</xref></p>
      </sec>
      <sec id="article-542.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>NODAT is&#x000a0;more common in Black and Hispanic patients compared to Whites, which&#x000a0;might be because of&#x000a0;genetic polymorphisms among Black and Hispanic transplant recipients. NODAT incidence in the United States has been reported to be about 9.1% of patients at 3 months, 16% at 12 months, and 24% at 36 months post-transplantation. Also, NODAT has been estimated to&#x000a0;occur in about&#x000a0;4 to 25% of renal transplants, 2.5 to 25% of&#x000a0;liver transplants, 4 to 40% of&#x000a0;heart transplants, and 30 to 35% of&#x000a0;lung transplant recipients. The risk of NODAT increases in liver transplants if the patient&#x000a0;has&#x000a0;an HCV infection and can range between 40% and 60%<bold>.</bold> Some studies&#x000a0;report the range of NODAT to be from 7 to 30% in the first year after kidney transplantation. Also, the majority of organ recipients (about 76.5%) develop NODAT in the first 3 months. After 6 months, the incidence of DM is almost the same as the patients with no transplant. Using higher doses of&#x000a0;immunosuppressive medications after&#x000a0;transplant correlates with a higher incidence of NODAT.<xref ref-type="bibr" rid="article-542.r13">[13]</xref><xref ref-type="bibr" rid="article-542.r14">[14]</xref><xref ref-type="bibr" rid="article-542.r15">[15]</xref></p>
      </sec>
      <sec id="article-542.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of NODAT is almost as same as type 2 DM: increase in&#x000a0;insulin resistance and decrease in insulin secretion. In&#x000a0;NODAT, insulin hyposecretion seems to have a more important role in glucose intolerance. NODAT more likely occurs in patients who have other risk factors in developing DM type 2. Immunosuppression regimen is one of the leading causes of NODAT; this&#x000a0;acts by affecting insulin secretion and action.<xref ref-type="bibr" rid="article-542.r16">[16]</xref></p>
      </sec>
      <sec id="article-542.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>As with DM, most patients with&#x000a0;NODAT are asymptomatic. The detection of many patients will be due to inpatient glucose monitoring and hyperglycemia on laboratory tests after&#x000a0;transplant surgery. Hence, glucose testing is in the recommendations for post-transplant screening in all transplant patients; this can result in early detection of NODAT. Symptoms&#x000a0;are the same as in non-transplant DM patients and include&#x000a0;polyuria, polydipsia, polyphagia, weight loss, blurry vision, neuropathy, numbness of extremities, and symptoms of infection.&#x000a0; The physical&#x000a0;exam includes vital signs, the extent of hydration, funduscopic eye exam, vascular and neurologic examinations, and a foot assessment. The physical examination findings&#x000a0;might be unrevealing, although observable end-organ damage may occur.</p>
      </sec>
      <sec id="article-542.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>NODAT is predictable by&#x000a0;evaluation of&#x000a0;the risk factors such as pre-diabetic status and obesity.&#x000a0;Some studies suggest that assessment of&#x000a0;preoperative insulin resistance, insulin sensitivity, and beta-cell function (c-peptide levels) may be helpful to predict NODAT but remains unconfirmed by other studies.</p>
        <p>Guidelines that define the criteria for the diagnosis of NODAT are&#x000a0;identical to the diagnostic criteria in DM:</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms of diabetes and random plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L)</p>
          </list-item>
          <list-item>
            <p>Fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) which requires repetition on another day</p>
          </list-item>
          <list-item>
            <p>Two-hour plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT)</p>
          </list-item>
        </list>
        <p>OGTT&#x000a0;is the gold standard for NODAT diagnosis, especially in the&#x000a0;early stages of transplantation. Because of the reduction of red blood cell survival after transplant, the diagnosis of NODAT based on HbA1c is not accurate in the first 3 months after the transplantation and is therefore not recommended. Beyond 3 months, the new hemoglobin&#x000a0;would be&#x000a0;synthesized and glycated for the appropriate period, and HbA1c greater than or equal to 6.5 percent&#x000a0;can be utilized to diagnose NODAT. Even many studies don't recommend HbA1c alone&#x000a0;as a screening tool for NODAT&#x000a0;in the first year after transplant.<xref ref-type="bibr" rid="article-542.r3">[3]</xref><xref ref-type="bibr" rid="article-542.r17">[17]</xref><xref ref-type="bibr" rid="article-542.r18">[18]</xref><xref ref-type="bibr" rid="article-542.r12">[12]</xref><xref ref-type="bibr" rid="article-542.r19">[19]</xref></p>
        <p>Although hemoglobin A1c can be used is some patients to diagnose diabetes mellitus, in the setting of ESRD, RBC turnover makes this unreliable.</p>
        <p>Early detection of NODAT is helpful&#x000a0;as it&#x000a0;reduces the risk&#x000a0;and complications of DM. The recommendation is for post-transplantation screening for NODAT in all patients undergoing solid organ transplants. Transplantation centers perform the screening tests weekly in the first month and continue screening at months 3, 6, and 12 post-transplantation. After the first year, the risk of NODAT is lower, and the recommendation is for yearly screening.<xref ref-type="bibr" rid="article-542.r8">[8]</xref></p>
      </sec>
      <sec id="article-542.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Some of the factors that induce post-transplant hyperglycemia&#x000a0;are postoperative surgical stress, pain, and high doses of immunosuppressants.&#x000a0;Early detection of hyperglycemia is crucial because early optimization of inpatient plasma glucose&#x000a0;has&#x000a0;a beneficial effect on the long-term patient and graft survival. The goal for management&#x000a0;is adequate glycemic control to minimize hyperglycemia complications. The first steps for glycemic control should focus on non-pharmacological&#x000a0;factors that elevate blood glucose. These steps include&#x000a0;switching from more diabetogenic immunosuppressants to the less diabetogenic ones or alter the dose of the immunosuppressants with the view of optimizing glycemic control, e.g.,&#x000a0;reducing corticosteroid&#x000a0;dose. Sometimes by simply tapering the corticosteroids soon after transplant can control without medical therapy.</p>
        <p>However, clinicians should be thoughtful about the possibility of acute rejection.&#x000a0;If lifestyle modification and immunosuppressants adjustment are insufficient to control hyperglycemia, then pharmacotherapy should be initiated.&#x000a0;Significant numbers of&#x000a0;the patients require insulin therapy to manage postoperative hyperglycemia while in the hospital. In hospitalized patients, as a result of frequent changes in immunosuppressants doses and&#x000a0;varying nutritional intake, fluctuations of blood glucose levels are common. Intravenous (IV) insulin is a good initial&#x000a0;choice since it is easily titratable, which results in tight plasma glucose control and is safe, particularly post-transplant when graft function is&#x000a0;still unstable. Choosing between insulin and oral hypoglycemic agents depends on the severity of hyperglycemia. Based on the&#x000a0;IV insulin infusion requirement, subcutaneous insulin doses can be calculated after proper glycemic control or discharge. Oral hypoglycemic therapy at the time of discharge is an option in patients who&#x000a0;required low-dose insulin therapy in the inpatient setting. There are no known drug-drug interactions between immunosuppressants and oral antidiabetic agents.&#x000a0;</p>
        <p>Metformin is one of the more popular agents which improves insulin sensitivity. Often the glomerular filtration rate&#x000a0;increases&#x000a0;adequately with&#x000a0;well-functioning grafts so it can be used safely for most patients and is&#x000a0;the first-line oral agent in NODAT management.&#x000a0;Sulfonylureas enhance insulin secretion and are used in NODAT extensively. Their side effects can be post-transplant weight gain and hypoglycemia. Thiazolidinediones are selective agonists of the peroxisomal proliferator-activated receptor gamma and improve glucose tolerance and insulin sensitivity in NODAT. Thiazolidinediones are contraindicated in congestive heart failure and should be used with caution if there is graft malfunction. Repaglinide is a safe drug among the meglitinides and acts by inducing insulin secretion. Dipeptidyl peptidase-4 (DPP-4) antagonists&#x000a0;act by inhibiting the degradation of glucagon-like peptide 1, which results in&#x000a0;pancreatic insulin secretion. Among the DPP-4 antagonists, sitagliptin is a good choice in NODAT. Using incretin-based therapy such as vildagliptin and&#x000a0;sitagliptin needs to be avoided in liver impairment and renal insufficiency; their safety in NODAT is still under study.</p>
        <p>Because patients with&#x000a0;transplants are at increased risk of&#x000a0;hypoglycemia&#x000a0;and frequently have a concurrent history of heart disease, guidelines recommend an HbA1c goal of 7 to 7.5% in these patients. Studies demonstrated that in patients with hypertension and&#x000a0;congestive heart failure, using&#x000a0;ACEIs or ARBs has a significant role in&#x000a0;reducing the incidence of NODAT. Treatment of infections such as HCV should be a consideration before transplant.<xref ref-type="bibr" rid="article-542.r20">[20]</xref><xref ref-type="bibr" rid="article-542.r18">[18]</xref><xref ref-type="bibr" rid="article-542.r8">[8]</xref><xref ref-type="bibr" rid="article-542.r7">[7]</xref><xref ref-type="bibr" rid="article-542.r12">[12]</xref></p>
      </sec>
      <sec id="article-542.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Stress hyperglycemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-542.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>NODAT outcome is affected by different factors, including the type of organ transplant, age, obesity, other cardiovascular risk factors, and immunosuppressants. Studies show a higher mortality rate in patients with NODAT&#x000a0;compared to those with type 2 DM. NODAT decreases patient survival by increasing both cardiovascular events and&#x000a0;the risk of infections.&#x000a0;NODAT is associated with a higher prevalence&#x000a0;of rejection and post-transplant renal failure. Studies showed that graft survival in patients with NODAT was 48%, while it was 70% in a patient without NODAT. Also, studies demonstrate that in kidney transplant recipients, cardiovascular events are 2 to 3 fold more in NODAT in comparison with other patients. Additionally, diabetic microvascular complications develop rapidly&#x000a0;in patients with NODAT than traditional DM.<xref ref-type="bibr" rid="article-542.r21">[21]</xref><xref ref-type="bibr" rid="article-542.r22">[22]</xref><xref ref-type="bibr" rid="article-542.r18">[18]</xref></p>
      </sec>
      <sec id="article-542.s11" sec-type="Complications">
        <title>Complications</title>
        <p>NODAT can cause similar complications to traditional DM, including neuropathy,&#x000a0;ophthalmopathy,&#x000a0;nephropathy, ketoacidosis, and&#x000a0;episodes of hypoglycemia. Even though these manifestations are similar to DM, the rate at which they occur is remarkably accelerated. Other than the increased risk of transplant rejection, there is a higher incidence of infection and late cardiovascular events, which leads to a higher mortality rate.<xref ref-type="bibr" rid="article-542.r16">[16]</xref><xref ref-type="bibr" rid="article-542.r2">[2]</xref><xref ref-type="bibr" rid="article-542.r13">[13]</xref></p>
      </sec>
      <sec id="article-542.s12" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Endocrinologists</p>
          </list-item>
          <list-item>
            <p>Ophthalmologists</p>
          </list-item>
          <list-item>
            <p>Podiatrists</p>
          </list-item>
          <list-item>
            <p>Cardiologists</p>
          </list-item>
          <list-item>
            <p>Nephrologists</p>
          </list-item>
          <list-item>
            <p>Dietitians</p>
          </list-item>
          <list-item>
            <p>Diabetic nurse educator</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-542.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>NODAT management&#x000a0;should ideally start before the organ transplant. Pre-transplant patients should receive counseling regarding the risk factors of developing NODAT and the ways to prevent it. Attention to&#x000a0;avoid weight gain&#x000a0;is an established step&#x000a0;to prevent NODAT. Weight loss can prevent NODAT in overweight patients with prediabetic status. In high-risk groups such as obese patients,&#x000a0;the goal&#x000a0;should include weight loss with diet and&#x000a0;increasing physical activity with target weight loss of 5% to 10% of total body weight and following up with the dietitian before and after transplant. Patients should be advised to eat a healthy, low-calorie, and low-fat diet. Weight loss immediately after transplant is not recommended, as it will delay&#x000a0;wound healing.</p>
        <p>After being diagnosed with NODAT, as with DM, self-glucose monitoring and compliance with treatment are essential. Also, patients&#x000a0;should be aware of the importance of an annual eye exam, which is even more important than in traditional diabetes patients. NODAT patients are prone to&#x000a0;have an acceleration of cataracts due to the universal use of both corticosteroids and immunosuppressants. Foot exams should be part of every clinical visit.&#x000a0;Immunosuppressants place NODAT patients at increased risk of different infections, so&#x000a0;compliance with annual influenza and&#x000a0;pneumococcal vaccines&#x000a0;is critical&#x000a0;in this population. Those patients who desire to get pregnant should be encouraged to wait&#x000a0;at least 1 year after the transplantation to decrease the risk of rejection. The transplant team should be involved in all stages before, during, and after pregnancy to reduce&#x000a0;the comorbidities of&#x000a0;both mother and baby.<xref ref-type="bibr" rid="article-542.r3">[3]</xref><xref ref-type="bibr" rid="article-542.r18">[18]</xref></p>
      </sec>
      <sec id="article-542.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Coordination of care among all&#x000a0;team members, including nurses, internists, nutritionists, surgeons, endocrinologists, nephrologists and, infectious disease specialists, is an essential factor in the management of&#x000a0;pre-existing diabetes or NODAT in transplant patients. Adequate blood glucose control, as well as treatment of comorbidities, is the backbone&#x000a0;in the management of NODAT as it increases patient survival and decreases the risk of graft rejection. Selecting the right immunosuppressants with the appropriate dose is one of the steps to prevent NODAT, but the risk of developing diabetes after transplantation should be weighed against the risk of transplant rejection.&#x000a0;At the time of discharge, each caring team's responsibility is to explain the above&#x000a0;to the patient. Also, education coordination by the nurses and clinicians of the patient and the family about the medical therapies and their side effects is critical as it can impact the patient survival.<xref ref-type="bibr" rid="article-542.r3">[3]</xref><xref ref-type="bibr" rid="article-542.r7">[7]</xref> [Level 1]</p>
        <p>Diagnosis and management of NODAT require an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. Clinicians (MDs, DOs, NPs, PAs) will typically be the ones to diagnose the condition and order the lab tests. They will also place the initial orders for therapeutic management, which nursing will administer. Nursing will also be responsible for monitoring patient response and serum glucose, documenting and reporting back to the prescribing clinician. Pharmacists can make medication recommendations based on the patient's current drug profile, comorbid conditions, verify dosing, and report recommendations to the nurses or prescribers. [Level 5]</p>
      </sec>
      <sec id="article-542.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=542&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=542">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/diabetes/new-onset-diabetes-after-transplant/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=542">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/542/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=542">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-542.s16">
        <title>References</title>
        <ref id="article-542.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lane</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Dagogo-Jack</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Approach to the patient with new-onset diabetes after transplant (NODAT).</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>96</volume>
            <issue>11</issue>
            <fpage>3289</fpage>
            <page-range>3289-97</page-range>
            <pub-id pub-id-type="pmid">22058376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>New-Onset Diabetes After Renal Transplantation (NODAT): Is It a Risk Factor for Renal Cell Carcinoma or Renal Failure?</article-title>
            <source>Ann Transplant</source>
            <year>2019</year>
            <month>Feb</month>
            <day>04</day>
            <volume>24</volume>
            <fpage>62</fpage>
            <page-range>62-69</page-range>
            <pub-id pub-id-type="pmid">30713333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reiser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alachkar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Diabetes mellitus in the transplanted kidney.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">25221544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bay&#x000e9;s</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lauzurica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Granada</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fontser&#x000e9;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Salinas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation.</article-title>
            <source>Transplantation</source>
            <year>2004</year>
            <month>Jul</month>
            <day>15</day>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-30</page-range>
            <pub-id pub-id-type="pmid">15257035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spranger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kroke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000f6;hlig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ristow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boeing</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Adiponectin and protection against type 2 diabetes mellitus.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Jan</month>
            <day>18</day>
            <volume>361</volume>
            <issue>9353</issue>
            <fpage>226</fpage>
            <page-range>226-8</page-range>
            <pub-id pub-id-type="pmid">12547549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bay&#x000e9;s</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Granada</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Pastor</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lauzurica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salinas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sanmart&#x000ed;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Espinal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>416</fpage>
            <page-range>416-22</page-range>
            <pub-id pub-id-type="pmid">17229078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>New onset diabetes after transplantation (NODAT): an overview.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2011</year>
            <volume>4</volume>
            <fpage>175</fpage>
            <page-range>175-86</page-range>
            <pub-id pub-id-type="pmid">21760734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palepu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>New-onset diabetes mellitus after kidney transplantation: Current status and future directions.</article-title>
            <source>World J Diabetes</source>
            <year>2015</year>
            <month>Apr</month>
            <day>15</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-55</page-range>
            <pub-id pub-id-type="pmid">25897355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghisdal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le Meur</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lionet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halimi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rerolle</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Glowacki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lebranchu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Drouet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>El Housni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cochaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wissing</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Abramowicz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abramowicz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>TCF7L2 polymorphism associates with new-onset diabetes after transplantation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>2459</fpage>
            <page-range>2459-67</page-range>
            <pub-id pub-id-type="pmid">19713311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Coto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Corte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Selgas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Larrea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Campistol</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ruiz-Ortega</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>V</given-names>
              </name>
              <collab>Pharmacogenetics of Tacrolimus REDINREN Study Group</collab>
            </person-group>
            <article-title>KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients.</article-title>
            <source>Clin Transplant</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>E284</fpage>
            <page-range>E284-91</page-range>
            <pub-id pub-id-type="pmid">21355884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Ihm</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation.</article-title>
            <source>Transplantation</source>
            <year>2012</year>
            <month>May</month>
            <day>15</day>
            <volume>93</volume>
            <issue>9</issue>
            <fpage>900</fpage>
            <page-range>900-7</page-range>
            <pub-id pub-id-type="pmid">22377791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghisdal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van Laecke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abramowicz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abramowicz</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>New-onset diabetes after renal transplantation: risk assessment and management.</article-title>
            <source>Diabetes Care</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>181</fpage>
            <page-range>181-8</page-range>
            <pub-id pub-id-type="pmid">22187441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lima</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Skare</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jaworski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nisihara</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for new-onset diabetes mellitus after kidney transplantation (NODAT): a Brazilian single center study.</article-title>
            <source>Arch Endocrinol Metab</source>
            <year>2018</year>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>597</fpage>
            <page-range>597-601</page-range>
            <pub-id pub-id-type="pmid">30624499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Sampaio</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bunnapradist</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients.</article-title>
            <source>Clin Transplant</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>885</fpage>
            <page-range>885-91</page-range>
            <pub-id pub-id-type="pmid">21175848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davidson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dantal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kasiske</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Kiberd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krentz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Legendre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marchetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Markell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Woude</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <collab>International Expert Panel</collab>
            </person-group>
            <article-title>New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.</article-title>
            <source>Transplantation</source>
            <year>2003</year>
            <month>May</month>
            <day>27</day>
            <volume>75</volume>
            <issue>10 Suppl</issue>
            <fpage>SS3</fpage>
            <page-range>SS3-24</page-range>
            <pub-id pub-id-type="pmid">12775942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fulkerson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oakes</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wallia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus.</article-title>
            <source>J Endocr Soc</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>1314</fpage>
            <page-range>1314-1319</page-range>
            <pub-id pub-id-type="pmid">30430145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shabir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borrows</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharif</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation.</article-title>
            <source>Transpl Int</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-21</page-range>
            <pub-id pub-id-type="pmid">23279163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shivaswamy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boerner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.</article-title>
            <source>Endocr Rev</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-61</page-range>
            <pub-id pub-id-type="pmid">26650437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhattacharjee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rungta</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>An observational Prospective Study to Evaluate the Preoperative Risk Factors of New-onset Diabetes Mellitus after Renal Transplantation in a Tertiary Care Centre in Eastern India.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>610</fpage>
            <page-range>610-615</page-range>
            <pub-id pub-id-type="pmid">30294568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakkera</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heilman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Mazur</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hamawi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mekeel</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Hyperglycemia during the immediate period after kidney transplantation.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>853</fpage>
            <page-range>853-9</page-range>
            <pub-id pub-id-type="pmid">19339426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boudreaux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Canafax</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ascher</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Najarian</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fryd</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.</article-title>
            <source>Transplantation</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>376</fpage>
            <page-range>376-81</page-range>
            <pub-id pub-id-type="pmid">3307061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-542.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Revanur</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kingsmore</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Jaques</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Jindal</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation.</article-title>
            <source>Clin Transplant</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-94</page-range>
            <pub-id pub-id-type="pmid">11264633</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
